




*Pathological Features of Peripheral
Atherosclerosis:
Implication for Device Development*

*G Nakazawa
Tokai Univ.
Kanagawa, Japan*


Sites of Atherosclerosis In order of Frequency




Gender- Age- and Atherosclerosis



A




B




Atherosclerosis in the large arteries was semi-quantitatively scored on a scale of 0–8 according to the ratio of the atheroma-occupied area to the entire surface area: negligible (0 point, ratio = 0–1/20), minimal (2 points, 1/20–1/6), mild (4 points, 1/6–1/3), moderate (6 points, 1/3–2/3), and severe (8 points, 2/3–1) where as for coronary arteries it was based on stenosis.

Histological examples Coronary vs. Femoral



A, B, C, and D are
Coronary plaques
and E and F are
Femoral arteries

Percentage distribution of AHA lesion types in the different arteries stratified by age decade





Eccentric Fibrous plaque




Femoral

Carotid





Coronary





Early phase of atherosclerosis in different types of artery: Pathologic Intimal Thickening

Femoral

Carotid



Coronary





Eccentric Fibrous Plaque with Calcified Necrotic Core




Femoral

Carotid




Coronary




Eccentric Plaque with Large lipid Core and Thin Cap Fibroatheroma in 3 different beds




Femoral



Carotid



Coronary





Chronic Total Occlusion




Femoral

Carotid




Coronary




Plaque Rupture




Femoral



Carotid




Coronary




Plaque Erosion




... Femoral



Carotid




Coronary




Eruptive and Non-Eruptive Nodular Calcification


Femoral



Carotid






Coronary






Calcification in Lower Extremity Artery



Mönckeberg's Medial Calcification from Asymptomatic PVD Patients



Monckeberg's Medial Calcification from Symptomatic PVD Patients Requiring Amputation



**Circumferential
Medial Calcification**

Differences and Similarities Between Coronary and Peripheral Atherosclerosis



- The stages of atherosclerosis described in the coronary, carotid and aortic disease are also applicable in the peripheral arteries
- Peripheral arteries have a high frequency of Mönckeberg's medial calcification, a feature not present in coronary or carotid artery disease
- Lipid cores in femoral arteries are not as large as those in the coronary or carotid disease



Limitations of Current Technology for the treatment of PAD





Restenosis Rates after Percutaneous Interventions



| <i>Artery</i> | <i>Restenosis at 6 -12 months</i> |
|-----------------------|-----------------------------------|
| Coronary | |
| BMS | 18 - 30 % |
| DES | 0 -10 % |
| Carotid | 5 - 8 % (BMS) |
| Iliac | |
| Balloon angioplasty | 6 - 41 % |
| BMS | 3 - 32 % |
| SFA, Popliteal | |
| BMS | 8 - 44 % |
| DES | 0 - 10 % (23% at 2 years) |
| Below the knee | |
| BMS | 21 - 79 % |
| DES | 4 - 37 (SES), 77 (PES) % |

Modified from Deiter RS, and Laird JR. Endovascular Today 2004

45 yrs WF with Left
common iliac artery
stent placement 2.5
yrs before death



Lower Extremity Artery Stenting



Procedure

- ✓ Long lesion (require overlapping stent)
- ✓ Under-expansion or incomplete apposition due to calcification


Results

- ✓ Enhanced delayed healing
- ✓ High incidence of restenosis or re-occlusion

Biomechanical forces in the femoropopliteal stenting




Hip flexion/Knee bending (degree)
 0/0 70/20 90/90
 Walking Stair climbing






- No elongation
- Torsion was not critically evaluated - not observed
- Shortening and bending - major changes

| | Mid- SFA | Distal SFA | Popliteal | Popliteal Bending Radius/Angle |
|--------------------|----------|------------|-----------|--------------------------------|
| 70/20 (Shortening) | 5% | 14% | 9% | |
| 90/90 (Shortening) | 10% | 23% | 14% | 13 mm 63° |

Average values based on seven cadaver, 14 limb study



Stent fracture and Restenosis in SFA and popliteal arteries




Scheinert, D et al, JACC 2005



Iida, O et al, AJC 2006

DES Restenosis Associated with Stent Fracture (Coronary)

EES implanted in LOM, 6 months



Proximal



Distal

51 year old male, complained of shortness of breath then became unresponsive.

New Strategies for the Treatment of Atherosclerosis




- **Drug Eluting Balloon**

- has no metal struts that may cause continuous stimulation to the vessel and lead to sustained inflammation.
- has potential ability to evenly deliver the drug to the vessel wall. However, the best pharmacokinetics and the best formulation of DEB remain unknown.
- acute or subacute recoil may occur and dampen its efficacy especially in highly calcified arteries.



- **Self-expanding DES**

- causes less injury and less inflammation on the vessel at the time of deployment.
- is flexible, and has a lasting resistance to the fracture that is associated with stent failure.
- maintains the radial force and prevents the occurrence of recoil in long-term.
- However, the advantage above will be dampened in the presence of heavy calcification as frequently observed in peripheral arteries.


Drug deliver of DEB




■ PTX only ■ PTX + Iopromide (SeQuent)



Non-atherosclerotic Rabbit Iliac Model – 28 days









Vascular Response to DEB




At 28-days following treatment in Rabbit Iliac model

POBA **PTX only** **PTX + Iopromide (SeQuent)**



Dose-dependent Changes in Iliofemoral Arteries Following SeQuent DEB treatment at 14 days



Downstream vascular change following DEB treatment




At 7-days


Vascular Changes in the Coronary Band of the Hoof

REPEAT TREATMENT


Fibrinoid Necrosis




Platelet emboli



Left Coronary Band



Fibrin Thrombus with Crystalline material



Stable Neointima formation in Access BA9 (Devax) and late catch up of Neointimal Formation in Cypher stents


Access BA9

30 Days

90 Days

180 Days

365 Days




Cypher

30 Days


90 Days

180 Days

365 Days



Percent Stenosis and Injury in Axxess BA9 Self-Expanding Stent v. Cypher



| | Injury score | | | |
|------------|---------------|-------------|---------------|-------------|
| Axxess BA9 | 0.039 ± 0.029 | 0.60 ± 0.68 | 0.080 ± 0.097 | 0.31 ± 0.43 |
| Cypher | 0.44 ± 0.35 | 1.53 ± 0.94 | 1.68 ± 1.10 | 1.59 ± 0.84 |
| | p= 0.007 | p= 0.003 | p= 0.005 | p= 0.006 |
| | 30 days | 90 days | 180 days | 365 days |

Speculative Differences Between DEB and Self-expanding DES vs. balloon expandable DES



| | Balloon expandable DES | Drug-eluting Balloon | Self-expanding DES |
|---|---------------------------------------|--|-----------------------------------|
| Injury & acute inflammation at PCI | 3 to 4+ | 3 to 4+ | 1 to 2+ (w/o post dilatation) |
| Drug deliverability | 3 to 4+ | 1 to 3+ (depend on solvent) | 3 to 4+ (even distribution) |
| Resistance to Recoil | 3 to 4+ | 0 | >5+ |
| Reaction to polymer | 2 to 3+ | 0 | 2 to 3+ |
| Metal struts stimuli | 2 to 3+ | 0 | 3 to 4+ |
| Neointimal Growth | 1 to 2+ | 2 to 3+ (incomplete drug distribution) | 1 to 2+ |
| Late luminal narrowing (restenosis) | 2 to 3+ (fracture / late catch-up) | 3 to 4+ (acute - late recoil and late catch-up) | 1 to 2+ (continuous expansion) |
| Uncovered strut | 2 to 3+ | 0 | 1 to 2+ (w/o post dilation) |
| Endothelial recovery | Delayed (> 1 year) | Faster (6 to 9 months) | Delayed (> 1year) |
| Risk of Late thrombosis | 2 to 3+ | 0 to 1+ | 1 to 2+ (larger luminal area) |

Summary



-
- New technologies such as drug-eluting balloon (DEB) and self-expanding DES has potential advantages that will complement the limitation of current DES technology.
 - However, the improvement of DEB is still required to achieve better drug distribution and to prevent distal emboli.
 - The sustained radial force of self-expanding DES overcomes the “late-catch-up” phenomenon of balloon expandable DES, however, the superiority will be diminished in the presence of heavy calcification.
 - The innovation of biomaterial is further needed.

Acknowledgements



CVPath Institute, Inc.

Renu Virmani

Frank Kolodgie

Masataka Nakano

Fumiyuki Otsuka